Serum 25-hydroxyvitamin D concentration in childhood and risk of islet autoimmunity and type 1 diabetes : the TRIGR nested case-control ancillary study by TRIGR Investigators et al.
ARTICLE
Serum 25-hydroxyvitamin D concentration in childhood and risk
of islet autoimmunity and type 1 diabetes: the TRIGR nested
case–control ancillary study
Maija E. Miettinen1 & Sari Niinistö1 & Iris Erlund1,2 & David Cuthbertson3 & Anita M. Nucci4 & Jarno Honkanen5 &
Outi Vaarala5 & Heikki Hyöty6,7 & Jeffrey P. Krischer3 & Mikael Knip8,9,10,11 & Suvi M. Virtanen1,12,13,14 & TRIGR
Investigators
Received: 5 June 2019 /Accepted: 8 November 2019
# The Author(s) 2020
Abstract
Aims/hypothesis Our aim was to study the association between serum 25-hydroxyvitamin D (25OHD) concentration and islet
autoimmunity and type 1 diabetes in children with an increased genetic risk of type 1 diabetes.
Methods Serum samples for 25OHD measurements were obtained in the Trial to Reduce IDDM in the Genetically at Risk
(TRIGR) ancillary study (Divia) from children in 15 countries. Case children (n = 244) were defined as having positivity for at
least two out of four diabetes-associated autoantibodies measured at any one sample. For each case child, two control children
were selected matched for country and date of birth (±1 year) (n = 488). Of the case children, 144 developed type 1 diabetes.
Serum 25OHDwas measured repeatedly in infancy and childhood and was compared according to age at the first seroconversion
(at 6, 12 and 18 months prior to and at seroconversion) and calendar age (0, 6, 12 and 18 months).
Results In children with islet autoimmunity, mean serum 25OHD concentration was lower 18 months prior to the age of first
seroconversion of the case children compared with the control children (57.7 vs 64.8 nmol/l, p = 0.007). In children with type 1
diabetes (n = 144), mean serum 25OHD concentration was lower 18 months prior to the age of the first seroconversion (58.0 vs
65.0 nmol/l, p = 0.018) and at the calendar age of 12 months (70.1 vs 75.9 nmol/l, p = 0.031) than in their control counterparts.
Analyses were adjusted for month of sample collection, human leucocyte antigen genotype, maternal type 1 diabetes and sex.
Conclusions/interpretation The results suggest that early postnatal vitamin D may confer protection against the development of
type 1 diabetes.
Trial registration ClinicalTrials.gov NCT00179777
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Abbreviations
DAISY Diabetes Auto Immunity Study in the Young
DIPP Diabetes Prediction and Prevention
GADA GAD autoantibody
IAA Insulin autoantibody
IA-2A Insulinoma-associated antigen-2 antibody
ICA Islet cell autoantibody
25OHD 25-Hydroxyvitamin D
TEDDY Environmental Determinants of Diabetes in the
Young
TRIGR Trial to Reduce IDDM in the Genetically at Risk
VDR Vitamin D receptor
ZnT8A Zinc transporter-8 autoantibody
Introduction
Type 1 diabetes is an immune-mediated disease in which
insulin-producing beta cells in the pancreas are damaged.
The preclinical phase of the disease can last from months to
even decades [1] and is characterised by the presence of
diabetes-associated autoantibodies, the most important of
which are islet cell autoantibodies (ICAs), insulin autoanti-
bodies (IAAs), insulinoma-associated antigen-2 autoanti-
bodies (IA-2As), GAD autoantibodies (GADAs) and zinc
transporter-8 autoantibodies (ZnT8As).
Vitamin D deficiency during the fetal period, infancy
or childhood is one of the environmental factors
implicated in the aetiology of type 1 diabetes, because
of the active role of vitamin D in regulating the immune
system. In previous studies investigating the association
between vitamin D and type 1 diabetes, emphasis has
been on either serum 25-hydroxyvitamin D (25OHD)
concentration (regarded as a marker of vitamin D stores)
arising from dietary and supplemental vitamin D intake or
on vitamin D metabolism-related genetic factors.
Large birth cohort studies that have invited participants
based on an increased genetic risk for type 1 diabetes have
analysed the association between serum 25OHD concen-
tration and type 1 diabetes. The Finnish Diabetes
Prediction and Prevention (DIPP) study [2,3] and the
Diabetes Auto Immunity Study in the Young (DAISY)
[4] did not find any association between serum 25OHD
concentration and risk of islet autoimmunity or type 1
diabetes at birth or during childhood, whereas the
Environmental Determinants of Diabetes in the Young
(TEDDY) study reported an association between low
serum 25OHD concentration during childhood and
increased risk of islet autoimmunity [5]. A Norwegian
study found an association between maternal low serum
25OHD concentrations and increased risk for type 1 diabe-
tes in the offspring [6], whereas in Finland such an associ-
ation was not seen in a similar study setting [7]. Two other
large studies from Norway and Denmark did not find an
association between type 1 diabetes and serum 25OHD
concentration at multiple time points from the first
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trimester of pregnancy until birth, or between type 1 diabe-
tes and neonatal 25OHD concentration measured from
dried blood spots [8,9].
Studies that have evaluated intake of vitamin D from the
diet and/or supplements in relation to the risk of islet autoim-
munity and type 1 diabetes, have produced mixed results [10].
In addition to the dietary intake, several factors modify serum
25OHD concentration including genetic factors and the
amount of sunlight. Therefore, it may be challenging to deter-
mine whether higher intake of vitamin D from the diet or
supplements has resulted in an improved vitamin D status,
especially if the amount of recommended supplementation
has been low. In Finland, a relatively high amount of daily
vitamin D supplementation (50 μg) was recommended to
infants during the first year of life in the 1960s. In a prospec-
tive birth cohort study, the risk of type 1 diabetes was found to
be reduced by 80% in those receiving regular vitamin D
supplementation, but the number of diabetes cases was low
[11].
Vitamin D metabolism-related genetic factors have shown
associations with type 1 diabetes but in genome-wide associ-
ation studies only one SNP has reached statistical significance
(rs10877012 in the CYP27B1 gene) [12]. In the TEDDY
study, it was noticed that the association between serum
25OHD concentration and islet autoimmunity was stronger
among carriers of a genotype of a certain SNP (rs7975232)
in VDR, the vitamin D receptor (VDR) gene [5]. Also in a
recent Norwegian study, the association between serum
25OHD concentration at birth and risk of type 1 diabetes
depended on the VDR genotype (rs11568820) [13]. VDR is
known to regulate expression of hundreds of genes of which
several are related to the function of the immune system [14].
The disease process of type 1 diabetes may start early in
infancy with mainly unknown factors causing changes in the
immune system even before the islet autoantibodies can be
detected [15]. Based on the existing evidence, the possible
role of vitamin D in the disease process of type 1 diabetes or
importance of timing of inadequate vitamin D supply is not
clear and may depend on the population and vitamin D status.
Our aim was to investigate the possible role of serum 25OHD
concentration during early childhood as a predictor of later
risk of developing islet autoimmunity or clinical type 1 diabe-
tes, both according to the age in relation to the first serocon-
version and calendar age.
Methods
Study population The current study is based on samples
collected in the Trial to Reduce IDDM in the Genetically at
Risk (TRIGR) cohort (ClinicalTrials.gov registration no.
NCT00179777). The TRIGR study is an international
double-blind randomised clinical trial of 2159 infants with
HLA-conferred disease susceptibility and a first-degree rela-
tive with type 1 diabetes recruited between 2002 and 2007 in
15 countries [16]. The inclusion criteria of the TRIGR study
included both certain HLA-conferred genotypes known to
increase the risk of type 1 diabetes and a first-degree relative
with type 1 diabetes [16]. In the TRIGR study, an extensively
hydrolysed casein infant formula was compared with a regular
formula based on cow’s milk. All participating infants were
followed until the youngest child turned 10 years of age.
Blood samples were collected at intervals of 3–12 months.
The Divia ancillary study of the TRIGR cohort tests hypoth-
eses related to the immune system, diet and virus infections in
the development of type 1 diabetes. All children within the
TRIGR study that developed islet autoimmunity (positivity
for at least two out of four autoantibodies measured) were
included as ‘cases’ in the TRIGR Divia ancillary study. For
each case child (n = 244), two control children (n = 488) were
randomly selected from children that did not develop positiv-
ity for two or more autoantibodies, matched for date of birth
(±1 year) and country. The same matched control children
were used also for those children that developed type 1 diabe-
tes (n = 144). Written informed consent was collected from all
families, signed by the legal guardian of the child. The study
was approved by the ethics committees of all participating
centres and was conducted according to the standards of the
Declaration of Helsinki.
Islet autoimmunity Case children (n = 244) were defined as
those with positivity, at any one sample, for two or more of the
following autoantibodies: ICA, IAA, IA-2A and GADA.
Autoantibodies were quantified with the use of specific
radiobinding assays in the Scientific Laboratory, Children’s
Hospital, University of Helsinki, Helsinki, Finland [16].
HLA genotyping HLA genotyping for the selected DQB1 and
DQA1 alleles was performed using sequence-specific oligo-
nucleotide hybridisation with the following genotypes
regarded as eligible: (1) HLA DQB1*02/DQB1*03:02 (high
risk); (2)HLADQB1*03:02/x (x notDQB1*02,DQB1*03:01
or DQB1*06:02) (moderate risk); (3) HLA DQA1*05-
DQB1*02/y (y not DQA1*02:01-DQB1*02, DQB1*03:01,
DQB1*06:02 or DQB1*06:03) (mild risk); and (4) HLA
DQA1*03-DQB1*02/y (y not DQA1*02:01-DQB1*02,
DQB1*03:01, DQB1*06:02 orDQB1*06:03) (rare mild risk)
[16].
Serum 25OHD analyses The serum samples were collected
during 2002–2017. The samples were stored frozen at
−70°C until analysed. Serum 25OHD concentration was
determined by a chemiluminescent microparticle immunoas-
say by Architect i system (Abbott Laboratories, Abbott Park,
IL, USA). The inter-assay CVof 25OHD was 4.3% and 3.4%
at the levels of 35 nmol/l and 104 nmol/l, respectively. Bias
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compared to all-laboratory trimmed means in the Vitamin D
International External Quality Assessment Scheme (DEQAS)
was 6.4 ± 9.3% (mean ± SD), which is considered satisfactory.
Furthermore, the laboratory participated in a standardisation
study comparing the Architect method with LC–tandem MS
[17], showing excellent agreement between the two methods
at 25OHD concentrations relevant to this study. In this study, a
serum 25OHD concentration of <30 nmol/l was considered as
severe vitamin D deficiency.
Statistical analyses The average 25OHD concentration
(nmol/l) across all age points was calculated for each partici-
pant. Separate averages for each participant were calculated
based on the season of sample collection. Descriptive statistics
based on these averages (means, SD and 95% CI) were calcu-
lated based on participant type (case or control), region, HLA
type and season of sample collection and compared using
general linear models. Conditional logistic regression models
were used to assess the odds of islet autoimmunity for 1 nmol/l
increase in 25OHD concentration. To account for possible
confounding, we evaluated the associations between back-
ground variables and serum 25OHD concentrations. As
expected, serum 25OHD concentrations were lower during
the winter than during the summer. To adjust for this
effect, month of sample collection was included in the
conditional logistic regression models. All analyses were
adjusted additionally for factors known to associate with
the risk of type 1 diabetes (HLA genotype, maternal type
1 diabetes and sex). A p value <0.05 was considered
statistically significant. The analyses were performed
using SAS v9.4 (SAS, Cary, NC, USA). The TRIGR
study is originally a clinical trial, but since no differences
were detected between the treatment arm and the control arm
[18], the original study setting did not require additional
adjusting.
Results
The distribution of the children according to the country or
region and HLA genotype is shown in Table 1. Mean serum
25OHD concentration varied in different regions with chil-
dren from Northern Europe (Finland and Sweden) having
the lowest concentrations, and children from Southern
Europe the highest concentrations (Table 2). Serum concen-
trations were higher in samples collected during the summer
months than winter months (Table 2). No significant associa-
tion was found between serum 25OHD concentration and
birthweight (p = 0.89), mode of birth (p = 0.74), gestational
age (p = 0.47), maternal age (p = 0.32) or maternal education
(p = 0.35).
The median age for the first seroconversion was 2.0 years
(interquartile range 1.0–4.0). Of the case children (n = 244),
144 developed type 1 diabetes, the mean age of diagnosis
being 6.0 years (interquartile range 2.9–9.4).
Among the children that developed islet autoimmunity, the
mean serum 25OHD concentration was lower 18months prior
to the age of the first seroconversion in the case children
(57.7 nmol/l) compared with that of the control children at
the corresponding age (64.8 nmol/l) (p = 0.007) (Table 3).
Among children that developed type 1 diabetes (n = 144),
the mean serum 25OHD concentration was lower 18 months
prior to the age of the first seroconversion (58.0 vs 65.0 nmol/
l) (p = 0.018) than in their control counterparts at the corre-
sponding age, and at 12 months of age (70.1 vs 75.9 nmol/l)
(p = 0.031) (Tables 3, 4). All analyses were adjusted for month
Table 1 Distribution of the
case children (with positivity for
at least two islet autoantibodies)
and control children in relation to
the country or region and HLA
genotype
Characteristic Case
children
n (%)
Control
children
n (%)
Country/region
Northern Europe (Finland, Sweden) 60 (24.6) 120 (24.6)
Canada 68 (27.9) 136 (27.9)
USA 39 (16.0) 78 (16.0)
Australia 9 (3.7) 18 (3.7)
Central Europe I (Czech Republic, Estonia, Hungary, Poland) 38 (15.6) 76 (15.6)
Central Europe II (Germany, Luxembourg, Netherlands, Switzerland) 23 (9.4) 46 (9.4)
Southern Europe (Italy, Spain) 7 (2.9) 14 (2.9)
HLA genotype
HLA-DQB1*0302/DQA1*05-DQB1*02 90 (36.9) 117 (24.0)
HLA-DQB1*03:02/x (x not DQB1*02, DQB1*03:01 or DQB1*06:02) 96 (39.3) 208 (42.6)
HLA-DQA1*05-DQB1*02/y (y not DQA1*02:01-DQB1*02, DQB1*03:01,
DQB1*06:02 or DQB1*06:03) and HLA-DQA1*03-DQB1*02/y (y not
DQA1*02:01-DQB1*02, DQB1*03:01, DQB1*06:02 or DQB1*06:03)
58 (23.8) 163 (33.4)
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of sample collection, HLA genotype, maternal type 1 diabetes
and sex.
Only 3% of the case children and 2% of the control chil-
dren had severe vitamin D deficiency at any time point (serum
25OHD concentration <30 nmol/l) (p = 0.27).
Discussion
In this study, we investigated the association between serum
25OHD concentration during early childhood and the devel-
opment of islet autoimmunity and type 1 diabetes. Vitamin D
status was determined using two time scales: time in relation
to the age at the initial seroconversion and to the calendar age.
We found that the mean serum 25OHD concentration was
lower 18 months prior to the initial seroconversion in the case
children compared with their control children. In addition,
children who progressed to clinical type 1 diabetes had a
lower serum 25OHD concentration 18 months prior to the
initial seroconversion and at 12 months of age compared with
control children. All other time points showed similar vitamin
D status in case and control children.
The strengths of the present study include a unique sample
set. The measurement of serum 25OHD concentration from
multiple time points as well as from multiple study locations
together with information on the HLA-conferred genetic risk
allowed us a more detailed analysis of vitamin D status as a
possible determinant of the risk for islet autoimmunity and
type 1 diabetes. In addition, the fact that we only included
those with two or more diabetes-associated autoantibodies
confirms the reliability of the islet autoimmunity status.
Most importantly, in addition to the calendar age, we were
able to analyse the association between the disease process
of type 1 diabetes and vitamin D status in relation to the age
at initial seroconversion. The inclusion of multiple time points
prior to the first seroconversion provided information on the
importance of timing of inadequate vitamin D supply.
Our results do not support a strong role for vitamin D in the
disease process leading to type 1 diabetes. This is consistent
with results from the DIPP and DAISY birth cohort studies
[2–4]. Recent findings suggest that vitamin D deficiency may
be a risk factor for those carrying certain genotypes of the VDR
gene [5,13]. A limitation of the present study is the lack of
genetic data to assess whether the differences that were detect-
ed would be stronger when analysed according to the genetic
factors that affect vitamin D metabolism. Also, due to inade-
quate statistical power, we were not able to analyse the associ-
ation separately according to country, region or ethnicity. A
further challenge is the fact that participants in the TRIGR
study represent a specific high-risk population in terms of type
1 diabetes, since the inclusion criteria included both a genetic
HLA-conferred risk and a first-degree relative with type 1
diabetes. The TRIGR, the TEDDY and the DIPP studies all
have distinct study populations, inclusion criteria and defini-
tion of islet autoimmunity. Therefore, the results cannot be
directly compared or generalised to other populations. For
Table 2 Mean serum 25OHD concentration (nmol/l) across all age points in relation to the country or region, HLA genotype and season of sample
collection
Characteristic Case children (N = 244) Control children (N = 488)
Mean (SD) 25OHD 95% CI Mean (SD) 25OHD 95% CI
Overall 65.5 (22.4) 62.6, 68.3 67.2 (22.4) 65.2, 69.2
Country/region
Northern Europe (Finland, Sweden) 54.0 (15.1) 50.1, 57.9 54.6 (18.5) 51.3, 58.0
Canada 69.4 (19.6) 64.6, 74.1 71.2 (17.5) 68.3, 74.2
USA 69.9 (23.7) 62.3, 77.6 67.9 (19.3) 63.6, 72.3
Australia 65.2 (14.0) 54.5, 76.0 73.1 (19.0) 63.6, 82.5
Central Europe I (Czech Republic, Estonia, Hungary, Poland) 69.0 (29.8) 59.2, 78.8 74.2 (30.5) 67.2, 81.2
Central Europe II (Germany, Luxembourg, Netherlands, Switzerland) 67.6 (24.2) 57.1, 78.1 71.8 (19.0) 66.2, 77.5
Southern Europe (Italy, Spain) 74.7 (24.1) 52.4, 97.0 70.8 (34.1) 51.2, 90.5
HLA genotype
HLA-DQB1*03:02/DQA1*05-DQB1*02 67.8 (23.9) 62.8, 72.8 69.2 (24.9) 64.6, 73.8
HLA-DQB1*03:02/x (x not DQB1*02, DQB1*03:01 or DQB1*06:02) 63.4 (22.6) 58.8, 68.0 68.3 (22.3) 65.3, 71.4
HLA-DQA1*05-DQB1*02/y (y not DQA1*02:01-DQB1*02, DQB1*03:01,
DQB1*06:02 or DQB1*06:03) and HLA-DQA1*03-DQB1*02/y (y not
DQA1*0201-DQB1*02, DQB1*03:01, DQB1*06:02 or DQB1*06:03)
65.3 (19.6) 60.1, 70.4 64.3 (20.4) 61.2, 67.5
Season of sample collection
Winter (November–May) 62.2 (25.0) 59.0, 65.4 64.1 (26.8) 61.7, 66.5
Summer (June–October) 72.8 (29.5) 68.7, 76.9 71.8 (29.1) 69.0, 74.6
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instance, it should be noted that results may be different in
vitamin D-deficient populations.
Our results indicate that if vitamin D status modifies the
risk of islet autoimmunity or type 1 diabetes in genetically
susceptible children, the possible effect may relate to the early
stage of the disease process (i.e. before seroconversion). It has
to be noted, though, that within this study setting, we were not
able to identify the possible effect of vitamin D at later stages
of the disease. The fact that half of the case children developed
islet autoimmunity at less than 2 years of age means they were
not all included when comparing vitamin D status between
case and control children 18 months before the first serocon-
version. Since a difference in vitamin D status between the
case and control children was identified 18 months before the
first seroconversion, this may imply that the possible effect is
stronger in those children who developed islet autoimmunity
at a slightly older age.
The proposed mechanisms of the possible association
between vitamin D and type 1 diabetes are related to the various
effects of vitamin D on the immune system. The importance of
vitamin D in the immune system is demonstrated by the pres-
ence of VDRs in a majority of the cells of the immune system
[19]. Immune cells also express vitamin D-activating enzymes
that locally convert inactive vitamin D to its active form [19].
Vitamin D may also interfere with gut microbiota [20,21] that
has also been associated with the early stages of the disease
process of type 1 diabetes [22], highlighting the complexity of
the possible association between vitamin D and type 1 diabetes.
Given that a clear difference in vitamin D status was seen in the
present study before seroconversion and that the children devel-
oped islet autoimmunity at a very young age (at a median age of
2 years), the possible developmental origin and therefore the
role of prenatal vitamin D status may be of interest. However,
several previous studies have failed to show an association
between 25OHD concentration during pregnancy or at birth
with the risk of type 1 diabetes in the child [8,9].
In the present study, vitamin D deficiency was rare. It has
been suggested that rather than being a cause of any disease,
poor vitamin D status may be a consequence of ill health [23].
In Finland, where vitamin D deficiency has been prevalent
until recent years, it was noticed that an increase in mean
serum 25OHD concentrations as a consequence of vitamin
D fortification, preceded a plateau in the increase in type 1
diabetes incidence [24]. It is not possible to evaluate any
causality in this temporal association.
The results suggest that early postnatal vitamin D may
confer protection against the development of type 1 diabetes.
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